Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Subscribe To Our Newsletter & Stay Updated
